60 Degrees Pharmaceuticals Inc (SXTPW)

Form 4 - Statement of changes in beneficial ownership of securities

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

License allows the Company to commence large-scale extraction of castanospermine from the seeds...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestonesMinimum...

Form 8-K - Current report

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website

Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway...

60 Degrees Pharmaceuticals Announces 2025 Annual Results

FY 2025 net product revenues increased 65% to $1,005,000Current shelf capacity exhausted after raise of $4...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its...

Form 424B5 - Prospectus [Rule 424(b)(5)]